Theodore Schroeder - Nabriva Therapeutics CEO Director
CEO
Mr. Theodore R. Schroeder is Chief Executive Officer of the Company. Prior to the Closing, Mr. Schroeder served as president, chief executive officer and director of Zavante. Previously, Mr. Schroeder cofounded Cadence Pharmaceuticals in 2004 and served as president, chief executive officer and a member of the board of directors until the companys acquisition by Mallinckrodt Pharmaceuticals in 2014. Prior to that, he held several roles at Elan Pharmaceuticals, including senior vice president of North American sales and marketing, and vice president and general manager of the hospital products business unit, a role he also held at Dura Pharmaceuticals before its acquisition by Elan Pharmaceuticals. Earlier in his career, Schroeder held a number of hospitalrelated sales and marketing positions with BristolMyers Squibb. He currently serves on the public company board of directors of Cidara Therapeutics, Otonomy and Collegium Pharmaceutical. In addition, he previously served on the board of directors of Hyperion Therapeutics, Incline Therapeutics and Trius Therapeutics until their respective acquisitions. Mr. Schroeder is a former chair of BIOCOM, the Southern California life sciences trade association since 2018.
| Age | 68 |
| Tenure | 7 years |
| Phone | 353 1 649 2000 |
| Web | https://www.nabriva.com |
Theodore Schroeder Latest Insider Activity
Tracking and analyzing the buying and selling activities of Theodore Schroeder against Nabriva Therapeutics stock is an integral part of due diligence when investing in Nabriva Therapeutics. Theodore Schroeder insider activity provides valuable insight into whether Nabriva Therapeutics is net buyers or sellers over its current business cycle. Note, Nabriva Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nabriva Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Theodore Schroeder over a year ago Payment of 431 shares by Theodore Schroeder of Nabriva Therapeutics subject to Rule 16b-3 |
Nabriva Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.652) % which means that it has lost $0.652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6853) %, meaning that it created substantial loss on money invested by shareholders. Nabriva Therapeutics' management efficiency ratios could be used to measure how well Nabriva Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Nabriva Therapeutics AG currently holds 5.22 M in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. Nabriva Therapeutics has a current ratio of 2.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Nabriva Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 2 records | CEO Age | ||
| David Gonyer | Evoke Pharma | 60 | |
| David RPh | Evoke Pharma | 60 | |
Management Performance
| Return On Equity | -2.69 | |||
| Return On Asset | -0.65 |
Nabriva Therapeutics Leadership Team
Elected by the shareholders, the Nabriva Therapeutics' board of directors comprises two types of representatives: Nabriva Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nabriva. The board's role is to monitor Nabriva Therapeutics' management team and ensure that shareholders' interests are well served. Nabriva Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nabriva Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gary Sender, Consultant | ||
| BA Esq, G Sec | ||
| Daniel Dolan, Chief Officer | ||
| Steven D, Chief Devel. Officer and Member of Management Board | ||
| Jodi VanDerveer, VP HR | ||
| Werner Heilmayer, VP IP | ||
| Colin MD, CEO and Member of Management Board | ||
| Theodore Schroeder, CEO Director | ||
| MBA MD, Chief Officer |
Nabriva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nabriva Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.69 | |||
| Return On Asset | -0.65 | |||
| Profit Margin | (1.48) % | |||
| Operating Margin | (1.29) % | |||
| Current Valuation | 3.29 M | |||
| Shares Outstanding | 3.2 M | |||
| Shares Owned By Insiders | 0.96 % | |||
| Shares Owned By Institutions | 8.77 % | |||
| Number Of Shares Shorted | 44.59 K | |||
| Price To Earning | (0.48) X |
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |